Evidence map›Paper›PMID 28653978›Full record

ArticleBehavioral sciences (Basel, Switzerland)2017

Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings.

Boadie W Dunlop, Jaclyn Gray, Mark H Rapaport

6 registry-linked trialsAbstract read
In one paragraph

Article in Behavioral sciences (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04710394 nacompletednot on this mapstarted 2021, after this paper: background citation

Efficacy of Bimodal Visual-Olfactory Training in Participants With COVID-19 Resultant Hyposmia or Anosmia Using Participant-Preferred Scents

TypeinterventionalSponsorWashington University School of MedicineRan2021 to 2022Enrolled240ConditionsAnosmia, Covid19, Ageusia, HyposmiaArmsSmell Training
NCT04789499 phase2completednot on this mapstarted 2021, after this paper: background citation

Smell in Covid-19 and Efficacy of Nasal Theophylline

TypeinterventionalSponsorWashington University School of MedicineRan2021 to 2021Enrolled51ConditionsCovid19, Anosmia, Olfactory Disorder, Covid-19 PandemicArmsTheophylline Powder, Placebo Comparator
NCT05216614 phase2withdrawnnot on this mapstarted 2021, after this paper: background citation

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)

TypeinterventionalSponsorWashington University School of MedicineRan2021 to 2022Enrolled0ConditionsCOVID-19, Olfactory Disorder, ParosmiaArmsFluvoxamine, Placebo
NCT05445921 phase1 / phase2completednot on this mapstarted 2022, after this paper: background citation

Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction: A Prospective Pilot Study

TypeinterventionalSponsorWashington University School of MedicineRan2022 to 2022Enrolled20ConditionsAnosmia, Hyposmia, Parosmia, Olfactory DisorderArmsStellate Ganglion Block
NCT05947643 phase2completednot on this mapstarted 2022, after this paper: background citation

Smell in COVID-19 and Efficacy of Nasal Theophylline 3

TypeinterventionalSponsorWashington University School of MedicineRan2022 to 2025Enrolled77ConditionsCOVID-19Armstheophylline, Placebo
NCT06253806 phase2completednot on this mapstarted 2023, after this paper: background citation

Stellate Ganglion Block for the Treatment of COVID-19-Induced Parosmia: Double-Blinded, Placebo-Controlled Randomized Clinical Trial

TypeinterventionalSponsorWashington University School of MedicineRan2023 to 2024Enrolled48ConditionsCOVID-19-Induced ParosmiaArmsStellate Ganglion Block, Placebo Sham Injection
3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Trial
  2. Efficacy of forskolin as a promising therapy for chronic olfactory dysfunction post COVID-19.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Effects ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  15. Review
  16. The minimal important difference in obsessive-compulsive disorder: An analysis of double-blind SSRI trials in adults.European psychiatry : the journal of the Association of European Psychiatrists · 2024
    Article
  17. PsiOvi Staging Model for Schizophrenia (PsiOvi SMS): A New Internet Tool for Staging Patients with Schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2024
    Article
  18. Article
  19. Dr. Johnstone et al. Reply to Dr. Hamilton.Journal of the American Academy of Child and Adolescent Psychiatry · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Boadie W DunlopDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive, 3rd Floor, Atlanta, GA 30329, USA. bdunlop@emory.edu.
Jaclyn GrayDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive, 3rd Floor, Atlanta, GA 30329, USA. jaclyn.gray@emory.edu.
Mark H RapaportDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive, 3rd Floor, Atlanta, GA 30329, USA. mark.h.rapaport@emory.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although there is great interest in the improving the ability to track patients' change over time in routine clinical care settings, no standardized transdiagnostic measure is currently available for busy clinicians to apply. The Clinical Global Impression (CGI) scales are simple measures widely used as outcomes in psychiatric clinical trials. However, the CGI suffers from poorly defined scoring anchors. Efforts to improve the anchors by enhancing the anchor descriptions have proven useful but are limited by being disease-specific, thereby acting as a barrier to the routine clinical adoption of the CGI. To inform the development of more broadly applicable CGI scoring anchors, we surveyed 24 clinical trial investigators, asking them to rank-order seven elements that inform their CGI-Severity (CGI-S) scoring. Symptom severity emerged as the most important element in determining CGI-S scores; the functional status of the patient emerged as a second element. Less importance was given to self-report symptom scores, staff observations, or side effects. Relative rankings of the elements' importance did not differ by investigators' experience nor time usually spent with patients. We integrated these results with published illness-specific CGI anchors to develop the Transdiagnostic CGI (T-CGI), which employs standardized scoring anchors applicable across psychiatric illnesses. Pending validity and reliability evaluations, the T-CGI may prove well-suited for inclusion in routine clinical settings and for incorporation into electronic medical records as a simple and useful measure of treatment efficacy.

Indexed as

anxiety disordersmood disorderspharmacotherapypsychotherapypsychotic disordersrating scale

Identifiers

PMID28653978
PMCPMC5618048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.